Point Therapeutics Achieves Desired Tumor Response in Talabostat Trial

Point Therapeutics has achieved the desired tumor response criteria with its lead compound, talabostat, in its Phase II non-small cell lung cancer (NSCLC) clinical trial.

This trial evaluates talabostat in combination with docetaxel in patients with Stage IIIb/IV NSCLC who have failed a platinum-based therapy.